Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas

Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas

Abstract CD20 is an established therapeutic target in B-cell malignancies. The CD20 × CD3 bispecific antibody mosunetuzumab has significant efficacy in B-cell non-Hodgkin lymphomas (NHLs). Because target antigen loss is a recognized mechanism of resistance, we evaluated CD20 expression relative to c...

Full description

Saved in:
Bibliographic Details
Main Authors: Stephen J. Schuster, Ling‐Yuh Huw, Christopher R. Bolen, Victor Maximov, Andrew G. Polson, Katerina Hatzi, Elisabeth A. Lasater, Sarit Assouline, Nancy L. Bartlett, Lihua E. Budde, Matthew J. Matasar, Hartmut Koeppen, Emily Piccione, Deanna Wilson, Michael C. Wei, Shen Yin, Elicia Penuel
Format: Artigo
Language:English
Published: 2023
Online Access:https://doi.org/10.1182/blood.2023022348
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1182/blood.2023022348

Similar Items